Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): a phase 3, randomised, non-inferiority trial-Reference-Cited by-同舟云学术

Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): a phase 3, randomised, non-inferiority trial

Published:2011-07 Issue:9787 Volume:378 Page:229-237
ISSN:0140-6736
Container-title:The Lancet
language:en
Short-container-title:The Lancet

Author:

Cohen Calvin J,Andrade-Villanueva Jaime,Clotet Bonaventura,Fourie Jan,Johnson Margaret A,Ruxrungtham Kiat,Wu Hao,Zorrilla Carmen,Crauwels Herta,Rimsky Laurence T,Vanveggel Simon,Boven Katia

Publisher

Elsevier BV

Subject

General Medicine

Reference31 articles.

1. Antiretroviral treatment of adult HIV infection 2010 Recommendations of the International AIDS Society—USA Panel;Thompson;JAMA,2010

2. Safety and tolerance of efavirenz in different antiretroviral regimens: results from a national multicenter prospective study in 1,033 HIV-infected patients;Pérez-Molina;HIV Clin Trials,2002

3. Short-term antiviral activity of TMC278—a novel NNRTI—in treatment-naive HIV-1-infected subjects;Goebel;AIDS,2006

4. Efficacy and safety of TMC278 in antiretroviral-naive HIV-1 patients: week 96 results of a phase IIb randomized trial;Pozniak;AIDS,2010

5. Wilkin A, Pozniak AL, Morales-Ramirez J, et al. TMC278 shows favorable tolerability and non-inferior efficacy compared to efavirenz over 192 weeks in HIV-1-infected treatment-naive patients. 19th Annual Canadian Conference on HIV/AIDS Research; Saskatoon, Canada; May 13–16, 2010. Abstract 7214.

Cited by 324 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Latest Developments in “Adaptive Enrichment” Clinical Trial Designs in Oncology;Therapeutic Innovation & Regulatory Science;2024-09-13

2. HIV and the Skin;Rook's Textbook of Dermatology;2024-03-19

3. A pseudo-response approach to constructing confidence intervals for the subset of patients expected to benefit from a new treatment;Journal of the Royal Statistical Society Series C: Applied Statistics;2024-01-02

4. Effectiveness and safety of bictegravir/emtricitabine/tenofovir alafenamide in HIV late presenters;International Journal of Antimicrobial Agents;2024-01

5. Fluorine in anti-HIV drugs approved by FDA from 1981 to 2023;European Journal of Medicinal Chemistry;2023-10